Immune microenvironment in tumor progression: Characteristics and challenges for therapy

Journal of Oncology

Volumn , Issue , 2012, Pages

  Chew, Valerie ^a   Toh, Han Chong ^b   Abastado, Jean Pierre ^a  

^a AGENCY FOR SCIENCE   (Singapore)

^b DIVISION OF MEDICAL ONCOLOGY   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; CHEMOKINE RECEPTOR CXCR4; CXCL1 CHEMOKINE; CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUOROURACIL; GAMMA INTERFERON; GEMCITABINE; IMATINIB; INTERLEUKIN 2; INTERLEUKIN 8; IPILIMUMAB; PACLITAXEL; SIPULEUCEL T; VINBLASTINE;

BREAST CANCER; CANCER CONTROL; CANCER GROWTH; CANCER IMMUNIZATION; CANCER IMMUNOLOGY; CANCER IMMUNOTHERAPY; CANCER PROGNOSIS; CARCINOMA CELL; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL (TOPIC); COLORECTAL CANCER; EPITHELIAL MESENCHYMAL TRANSITION; GASTROINTESTINAL STROMAL TUMOR; HUMAN; IMMUNE RESPONSE; IMMUNOMODULATION; INFLAMMATION; LIVER CANCER; LUNG CANCER; MELANOMA; METASTASIS; NONHUMAN; OVARY CANCER; PROSTATE CANCER; REVIEW; T LYMPHOCYTE; TUMOR MICROENVIRONMENT;

EID: 84866245257     PISSN: 16878450     EISSN: 16878469     Source Type: Journal    
DOI: 10.1155/2012/608406     Document Type: Review

References (134)

1. Chow M. T., Möller A., Smyth M. J., Inflammation and immune surveillance in cancer. Seminars in Cancer Biology 2012 22 1 23 32 2-s2.0-84857138799 10.1016/j.semcancer.2011.12.004
2. Smyth M. J., Dunn G. P., Schreiber R. D., Cancer immunosurveillance and immunoediting: the roles of immunity in suppressing tumor development and shaping tumor immunogenicity. Advances in Immunology 2006 90 1 50 2-s2.0-33646755569 10.1016/S0065-2776(06)90001-7 (Pubitemid 43765795)
3. Euvrard S., Kanitakis J., Claudy A., Skin cancers after organ transplantation. New England Journal of Medicine 2003 348 17 1681 1691 2-s2.0-0037464506 10.1056/NEJMra022137 (Pubitemid 36459475)
4. Sanchez E. Q., Marubashi S., Jung G., Levy M. F., Goldstein R. M., Molmenti E. P., Fasola C. G., Gonwa T. A., Jennings L. W., Brooks B. K., Klintmalm G. B., De novo tumors after liver transplantation: a single-institution experience. Liver Transplantation 2002 8 3 285 291 2-s2.0-18344365955 10.1053/jlts.2002.29350 (Pubitemid 34257212)
5. Zwald F. O., Christenson L. J., Billingsley E. M., Zeitouni N. C., Ratner D., Bordeaux J., Patel M. J., Brown M. D., Proby C. M., Euvrard S., Otley C. C., Stasko T., Melanoma in solid organ transplant recipients. American Journal of Transplantation 2010 10 5 1297 1304 2-s2.0-77951244434 10.1111/j.1600-6143. 2010.03078.x
6. Girardi M., Oppenheim D. E., Steele C. R., Lewis J. M., Glusac E., Filler R., Hobby P., Sutton B., Tigelaar R. E., Hayday A. C., Regulation of cutaneous malignancy by γδ T cells. Science 2001 294 5542 605 609 2-s2.0-0035914134 10.1126/science.1063916 (Pubitemid 32999559)
7. Smyth M. J., Thia K. Y. T., Street S. E. A., Cretney E., Trapani J. A., Taniguchi M., Kawano T., Pelikan S. B., Crowe N. Y., Godfrey D. I., Differential tumor surveillance by natural killer (NK) and NKT cells. Journal of Experimental Medicine 2000 191 4 661 668 2-s2.0-0034695880 10.1084/jem.191.4.661
8. Street S. E. A., Cretney E., Smyth M. J., Perforin and interferon- γ activities independently control tumor initiation, growth, and metastasis. Blood 2001 97 1 192 197 2-s2.0-0035165729 10.1182/blood.V97.1.192 (Pubitemid 32061260)
9. Van Den Broek M. F., Kägi D., Ossendorp F., Toes R., Vamvakas S., Lutz W. K., Melief C. J. M., Zinkernagel R. M., Hengartner H., Decreased tumor surveillance in perforin-deficient mice. Journal of Experimental Medicine 1996 184 5 1781 1790 2-s2.0-0029804782 (Pubitemid 26404469)
10. Dunn G. P., Bruce A. T., Ikeda H., Old L. J., Schreiber R. D., Cancer immunoediting: from immunosurveillance to tumor escape. Nature Immunology 2002 3 11 991 998 2-s2.0-0036852241 10.1038/ni1102-991 (Pubitemid 35363648)
11. Engel A. M., Svane I. M., Rygaard J., Werdelin O., MCA sarcomas induced in scid mice are more immunogenic than MCA sarcomas induced in congenic, immunocompetent mice. Scandinavian Journal of Immunology 1997 45 5 463 470 2-s2.0-0031004968 (Pubitemid 27198705)
12. Aggarwal B. B., Inflammation, a silent killer in cancer is not so silent! Current Opinion in Pharmacology 2009 9 4 347 350 2-s2.0-68849116474 10.1016/j.coph.2009.06.018
13. Aggarwal B. B., Shishodia S., Sandur S. K., Pandey M. K., Sethi G., Inflammation and cancer: how hot is the link? Biochemical Pharmacology 2006 72 11 1605 1621 2-s2.0-33750497844 10.1016/j.bcp.2006.06.029 (Pubitemid 44666739)
14. Balkwill F., Mantovani A., Inflammation and cancer: back to Virchow? The Lancet 2001 357 9255 539 545 2-s2.0-0035901090 10.1016/S0140-6736(00)04046-0 (Pubitemid 32173595)
15. Chew V., Chen J., Lee D., Loh E., Lee J., Lim K. H., Weber A., Slankamenac K., Poon R. T. P., Yang H., Ooi L. L. P. J., Toh H. C., Heikenwalder M., Ng I. O. L., Nardin A., Abastado J.-P., Chemokine-driven lymphocyte infiltration: an early intratumoural event determining long-term survival in resectable hepatocellular carcinoma. Gut 2012 61 3 427 438 2-s2.0-84857050018 10.1136/gutjnl-2011-300509
16. Hsu D. S., Kim M. K., Balakumaran B. S., Acharya C. R., Anders C. K., Clay T., Lyerly H. K., Drake C. G., Morse M. A., Febbo P. G., Immune signatures predict prognosis in localized cancer. Cancer Investigation 2010 28 7 765 773 2-s2.0-77954801902 10.3109/07357900903095755
17. Suzuki K., Kachala S. S., Kadota K., Shen R., Mo Q., Beer D. G., Rusch V. W., Travis W. D., Adusumilli P. S., Prognostic immune markers in non-small cell lung cancer. Clinical Cancer Research 2011 17 16 5247 5256 2-s2.0-80051688291 10.1158/1078-0432.CCR-10-2805
18. Pagès F., Galon J., Dieu-Nosjean M. C., Tartour E., Sautès-Fridman C., Fridman W. H., Immune infiltration in human tumors: a prognostic factor that should not be ignored. Oncogene 2010 29 8 1093 1102 2-s2.0-77649193013 10.1038/onc.2009.416
19. Chew V., Tow C., Teo M., Wong H. L., Chan J., Gehring A., Loh M., Bolze A., Quek R., Lee V. K. M., Lee K. H., Abastado J. P., Toh H. C., Nardin A., Inflammatory tumour microenvironment is associated with superior survival in hepatocellular carcinoma patients. Journal of Hepatology 2010 52 3 370 379 2-s2.0-77549084467 10.1016/j.jhep.2009.07.013
20. Weber C. E., Kuo P. C., The tumor microenvironment. Surgical Oncology. In press
21. Oltvai Z. N., Barabási A. L., Systems biology: life's complexity pyramid. Science 2002 298 5594 763 764 2-s2.0-0037174638 10.1126/science.1078563 (Pubitemid 35231516)
22. Bhowmick N. A., Neilson E. G., Moses H. L., Stromal fibroblasts in cancer initiation and progression. Nature 2004 432 7015 332 337 2-s2.0-9244227134 10.1038/nature03096 (Pubitemid 39551661)
23. Carmeliet P., Jain R. K., Angiogenesis in cancer and other diseases. Nature 2000 407 6801 249 257 2-s2.0-0034648765 10.1038/35025220
24. Weis S. M., Cheresh D. A., Tumor angiogenesis: molecular pathways and therapeutic targets. Nature Medicine 2011 17 11 1359 1370 2-s2.0-81255188940 10.1038/nm.2537
25. Sleeman J. P., Thiele W., Tumor metastasis and the lymphatic vasculature. International Journal of Cancer 2009 125 12 2747 2756 2-s2.0-70549104050 10.1002/ijc.24702
26. Mohseny A. B., Hogendoorn P. C. W., Concise review: mesenchymal tumors: when stem cells go mad. Stem Cells 2011 29 3 397 403 2-s2.0-79953000341 10.1002/stem.596
27. Ostrand-Rosenberg S., Sinha P., Myeloid-derived suppressor cells: linking inflammation and cancer. Journal of Immunology 2009 182 8 4499 4506 2-s2.0-65249138393 10.4049/jimmunol.0802740
28. Mantovani A., Schioppa T., Porta C., Allavena P., Sica A., Role of tumor-associated macrophages in tumor progression and invasion. Cancer and Metastasis Reviews 2006 25 3 315 322 2-s2.0-33845524204 10.1007/s10555-006-9001- 7 (Pubitemid 44922352)
29. Tosolini M., Kirilovsky A., Mlecnik B., Fredriksen T., Mauger S., Bindea G., Berger A., Bruneval P., Fridman W. H., Pagès F., Galon J., Clinical impact of different classes of infiltrating T cytotoxic and helper cells (Th1, Th2, Treg, Th17) in patients with colorectal cancer. Cancer Research 2011 71 4 1263 1271 2-s2.0-79951815749 10.1158/0008-5472.CAN-10-2907
30. Wilson J., Balkwill F., The role of cytokines in the epithelial cancer microenvironment. Seminars in Cancer Biology 2002 12 2 113 120 2-s2.0-0035999153 10.1006/scbi.2001.0419 (Pubitemid 34680740)
31. Balkwill F., Cancer and the chemokine network. Nature Reviews Cancer 2004 4 7 540 550 2-s2.0-3042822267 (Pubitemid 38868623)
32. Matzinger P., The danger model: a renewed sense of self. Science 2002 296 5566 301 305 2-s2.0-0037066427 10.1126/science.1071059 (Pubitemid 34303674)
33. Sims G. P., Rowe D. C., Rietdijk S. T., Herbst R., Coyle A. J., HMGB1 and RAGE in inflammation and cancer. Annual Review of Immunology 2010 28 367 388 2-s2.0-77952298772 10.1146/annurev.immunol.021908.132603
34. Bercovici N., Trautmann A., Revisiting the role of T cells in tumor regression. OncoImmunology 2012 1 3 346 350
35. Melbye M., Cote T. R., Kessler L., Gail M., Biggar R. J., High incidence of anal cancer among AIDS patients. The Lancet 1994 343 8898 636 639 2-s2.0-0028296461 10.1016/S0140-6736(94)92636-0 (Pubitemid 24087808)
36. Strauss D. C., Thomas J. M., Transmission of donor melanoma by organ transplantation. The Lancet Oncology 2010 11 8 790 796 2-s2.0-77955268790 10.1016/S1470-2045(10)70024-3
37. Stojanovic A., Cerwenka A., Natural killer cells and solid tumors. Journal of Innate Immunity 2011 3 4 355 364 2-s2.0-79959675835 10.1159/000325465
38. Pross H. F., Lotzova E., Role of natural killer cells in cancer. Natural Immunity 1993 12 4-5 279 292 2-s2.0-0027368830 (Pubitemid 23297445)
39. Weigelin B., Krause M., Friedl P., Cytotoxic T lymphocyte migration and effector function in the tumor microenvironment. Immunology Letters 2011 138 1 19 21 2-s2.0-79957674964 10.1016/j.imlet.2011.02.016
40. Flinsenberg T. W. H., Compeer E. B., Boelens J. J., Boes M., Antigen cross-presentation: extending recent laboratory findings to therapeutic intervention. Clinical and Experimental Immunology 2011 165 1 8 18 2-s2.0-79958148319 10.1111/j.1365-2249.2011.04411.x
41. 8+ T cells. Cancer Research 2003 63 14 4095 4100 2-s2.0-0042173089 (Pubitemid 36917932)
42. 8+ T cell tumor immunity: therapeutic B cell depletion enhances B16 melanoma growth in mice. Journal of Immunology 2010 184 7 4006 4016 2-s2.0-77951629658 10.4049/jimmunol.0903009
43. Almog N., Molecular mechanisms underlying tumor dormancy. Cancer Letters 2010 294 2 139 146 2-s2.0-77953362501 10.1016/j.canlet.2010.03.004
44. Eyles J., Puaux A. L., Wang X., Toh B., Prakash C., Hong M., Tan T. G., Zheng L., Ong L. C., Jin Y., Kato M., Prévost-Blondel A., Chow P., Yang H., Abastado J. P., Tumor cells disseminate early, but immunosurveillance limits metastatic outgrowth, in a mouse model of melanoma. Journal of Clinical Investigation 2010 120 6 2030 2039 2-s2.0-77953225810 10.1172/JCI42002
45. Browning M. J., Bodmer W. F., MHC antigens and cancer: implications for T-cell surveillance. Current Opinion in Immunology 1992 4 5 613 618 2-s2.0-0026693845 10.1016/0952-7915(92)90036-E
46. Reed J. C., Mechanisms of apoptosis avoidance in cancer. Current Opinion in Oncology 1999 11 1 68 75 2-s2.0-0033026714 10.1097/00001622-199901000-00014 (Pubitemid 29082059)
47. Zhang X., Nie D., Chakrabarty S., Growth factors in tumor microenvironment. Frontiers in Bioscience 2010 15 1 151 165 2-s2.0-77951227016 10.2741/3612
48. Ben-Baruch A., Inflammation-associated immune suppression in cancer: the roles played by cytokines, chemokines and additional mediators. Seminars in Cancer Biology 2006 16 1 38 52 2-s2.0-31344442461 10.1016/j.semcancer.2005.07. 006 (Pubitemid 43139708)
49. Gajewski T. F., Meng Y., Harlin H., Immune suppression in the tumor microenvironment. Journal of Immunotherapy 2006 29 3 233 240 2-s2.0-33746092947 10.1097/01.cji.0000199193.29048.56 (Pubitemid 44297291)
50. Huang B., Zhao J., Li H., He K. L., Chen Y., Mayer L., Unkeless J. C., Xiong H., Toll-like receptors on tumor cells facilitate evasion of immune surveillance. Cancer Research 2005 65 12 5009 5014 2-s2.0-20444432334 10.1158/0008-5472.CAN-05-0784 (Pubitemid 40827306)
51. Goel S., Duda D. G., Xu L., Munn L. L., Boucher Y., Fukumura D., Jain R. K., Normalization of the vasculature for treatment of cancer and other diseases. Physiological Reviews 2011 91 3 1071 1121 2-s2.0-79960096827 10.1152/physrev.00038.2010
52. Zou W., Regulatory T cells, tumour immunity and immunotherapy. Nature Reviews Immunology 2006 6 4 295 307 2-s2.0-33645286546 10.1038/nri1806
53. Middleton G. W., Annels N. E., Pandha H. S., Are we ready to start studies of Th17 cell manipulation as a therapy for cancer? Cancer Immunology, Immunotherapy 2012 61 1 1 7 2-s2.0-84856708250 10.1007/s00262-011-1151-y
54. 4+ T cells to T-regulatory cells. Cancer Research 2011 71 10 3505 3515 2-s2.0-79956131523 10.1158/0008-5472.CAN-10-4316
55. Staquicini F. I., Tandle A., Libutti S. K., Sun J., Zigler M., Bar-Eli M., Aliperti F., Pérez E. C., Gershenwald J. E., Mariano M., Pasqualini R., Arap W., Lopes J. D., A subset of host B lymphocytes controls melanoma metastasis through a melanoma cell adhesion molecule/MUC18-dependent interaction: evidence from mice and humans. Cancer Research 2008 68 20 8419 8428 2-s2.0-54249161032 10.1158/0008-5472.CAN-08-1242
56. Yang L., Carbone D. P., Tumor-host immune interactions and dendritic cell dysfunction. Advances in Cancer Research 2004 92 13 27 2-s2.0-7644237187 10.1016/S0065-230X(04)92002-7 (Pubitemid 39458111)
57. Chemin I., Zoulim F., Hepatitis B virus induced hepatocellular carcinoma. Cancer Letters 2009 286 1 52 59 2-s2.0-70349253352 10.1016/j.canlet.2008.12.003
58. Hatakeyama M., Helicobacter pylori and gastric carcinogenesis. Journal of Gastroenterology 2009 44 4 239 248 2-s2.0-65049086892 10.1007/s00535-009-0014-1
59. Mantovani A., Molecular pathways linking inflammation and cancer. Current Molecular Medicine 2010 10 4 369 373 2-s2.0-77953485565 10.2174/ 156652410791316968
60. Hodge D. R., Hurt E. M., Farrar W. L., The role of IL-6 and STAT3 in inflammation and cancer. European Journal of Cancer 2005 41 16 2502 2512 2-s2.0-27544476971 10.1016/j.ejca.2005.08.016 (Pubitemid 41540626)
61. Payne A. S., Cornelius L. A., The role of chemokines in melanoma tumor growth and metastasis. Journal of Investigative Dermatology 2002 118 6 915 922 2-s2.0-0036270898 10.1046/j.1523-1747.2002.01725.x (Pubitemid 34639168)
62. Yang L., Huang J., Ren X., Gorska A. E., Chytil A., Aakre M., Carbone D. P., Matrisian L., Richmond A., Lin P. C., Moses H. L., Abrogation of TGF β signaling in mammary carcinomas recruits Gr-1+CD11b+ myeloid cells that promote metastasis. Cancer Cell 2008 13 1 23 35 2-s2.0-37349100945 10.1016/j.ccr.2007. 12.004 (Pubitemid 350309741)
63. Balkwill F., The significance of cancer cell expression of the chemokine receptor CXCR4. Seminars in Cancer Biology 2004 14 3 171 179 2-s2.0-2342591450 10.1016/j.semcancer.2003.10.003 (Pubitemid 38586742)
64. Ben-Neriah Y., Karin M., Inflammation meets cancer, with NF- κ B as the matchmaker. Nature Immunology 2011 12 8 715 723 2-s2.0-80052014052 10.1038/ni.2060
65. Jemal A., Siegel R., Ward E., Hao Y., Xu J., Murray T., Thun M. J., Cancer statistics, 2008. CA Cancer Journal for Clinicians 2008 58 2 71 96 2-s2.0-41349099104 10.3322/CA.2007.0010 (Pubitemid 351521864)
66. Micalizzi D. S., Ford H. L., Epithelial-mesenchymal transition in development and cancer. Future Oncology 2009 5 8 1129 1143 2-s2.0-75649086115 10.2217/fon.09.94
67. Thiery J. P., Acloque H., Huang R. Y. J., Nieto M. A., Epithelial-mesenchymal transitions in development and disease. Cell 2009 139 5 871 890 2-s2.0-70450198396 10.1016/j.cell.2009.11.007
68. Savagner P., The epithelial-mesenchymal transition (EMT) phenomenon. Annals of Oncology 2010 21 7 vii89 vii92 2-s2.0-78649369742 10.1093/annonc/ mdq292
69. Toh B., Wang X., Keeble J., Sim W. J., Khoo K., Wong W.-C., Kato M., Prevost-Blondel A., Thiery J.-P., Abastado J.-P., Mesenchymal transition and dissemination of cancer cells is driven by myeloid-derived suppressor cells infiltrating the primary tumor. PLoS Biology 2011 9 9 e1001162 2-s2.0-80053336355 10.1371/journal.pbio.1001162
70. Santisteban M., Reiman J. M., Asiedu M. K., Behrens M. D., Nassar A., Kalli K. R., Haluska P., Ingle J. N., Hartmann L. C., Manjili M. H., Radisky D. C., Ferrone S., Knutson K. L., Immune-induced epithelial to mesenchymal transition in vivo generates breast cancer stem cells. Cancer Research 2009 69 7 2887 2895 2-s2.0-66149131111 10.1158/0008-5472.CAN-08-3343
71. Bonde A.-K., Tischler V., Kumar S., Soltermann A., Schwendener R. A., Intratumoral macrophages contribute to epithelial-mesenchymal transition in solid tumors. BMC Cancer 2012 12, article 35 2-s2.0-84862823626 10.1186/1471-2407-12-35
72. Belnoue E., Guettier C., Kayibanda M., Le Rond S., Crain-Denoyelle A. M., Marchiol C., Ziol M., Fradelizi D., Rénia L., Viguier M., Regression of established liver tumor induced by monoepitopic peptide-based immunotherapy. Journal of Immunology 2004 173 8 4882 4888 2-s2.0-6344258245 (Pubitemid 39387769)
73. Qian S. B., Li Y., Qian G. X., Chen S. S., Efficient tumor regression induced by genetically engineered tumor cells secreting interleukin-2 and membrane-expressing allogeneic MHC class I antigen. Journal of Cancer Research and Clinical Oncology 2001 127 1 27 33 2-s2.0-0034744321 10.1007/s004320000176 (Pubitemid 32128510)
74. Hoshida Y., Villanueva A., Kobayashi M., Peix J., Chiang D. Y., Camargo A., Gupta S., Moore J., Wrobel M. J., Lerner J., Reich M., Chan J. A., Glickman J. N., Ikeda K., Hashimoto M., Watanabe G., Daidone M. G., Roayaie S., Schwartz M., Thung S., Salvesen H. B., Gabriel S., Mazzaferro V., Bruix J., Friedman S. L., Kumada H., Llovet J. M., Golub T. R., Gene expression in fixed tissues and outcome in hepatocellular carcinoma. New England Journal of Medicine 2008 359 19 1995 2004 2-s2.0-57349090407 10.1056/NEJMoa0804525
75. Budhu A., Forgues M., Ye Q. H., Jia H. L., He P., Zanetti K. A., Kammula U. S., Chen Y., Qin L. X., Tang Z. Y., Wang X. W., Prediction of venous metastases, recurrence, and prognosis in hepatocellular carcinoma based on a unique immune response signature of the liver microenvironment. Cancer Cell 2006 10 2 99 111 2-s2.0-33747029250 10.1016/j.ccr.2006.06.016 (Pubitemid 44202603)
76. Galon J., Costes A., Sanchez-Cabo F., Kirilovsky A., Mlecnik B., Lagorce-Pagès C., Tosolini M., Camus M., Berger A., Wind P., Zinzindohoué F., Bruneval P., Cugnenc P. H., Trajanoski Z., Fridman W. H., Pagès F., Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 2006 313 5795 1960 1964 2-s2.0-33749319703 10.1126/science.1129139 (Pubitemid 44498003)
77. Clemente C. G., Mihm Jr. M. C., Bufalino R., Zurrida S., Collini P., Cascinelli N., Prognostic value of tumor infiltrating lymphocytes in the vertical growth phase of primary cutaneous melanoma. Cancer 1996 77 7 1303 1310 2-s2.0-0029925375 10.1002/(SICI)1097-0142(19960401)77:71303::AID-CNCR12>3.0. CO;2-5 (Pubitemid 26102328)
78. Menegaz R. A., Michelin M. A., Etchebehere R. M., Fernandes P. C., Murta E. F. C., Peri- and intratumoral T and B lymphocytic infiltration in breast cancer. European Journal of Gynaecological Oncology 2008 29 4 321 326 2-s2.0-47949124128
79. Zhang L., Conejo-Garcia J. R., Katsaros D., Gimotty P. A., Massobrio M., Regnani G., Makrigiannakis A., Gray H., Schlienger K., Liebman M. N., Rubin S. C., Coukos G., Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. New England Journal of Medicine 2003 348 3 203 213 2-s2.0-0037448353 10.1056/NEJMoa020177 (Pubitemid 36077915)
80. Dieu-Nosjean M. C., Antoine M., Danel C., Heudes D., Wislez M., Poulot V., Rabbe N., Laurans L., Tartour E., De Chaisemartin L., Lebecque S., Fridman W. H., Cadranel J., Long-term survival for patients with non-small-cell lung cancer with intratumoral lymphoid structures. Journal of Clinical Oncology 2008 26 27 4410 4417 2-s2.0-52449102477 10.1200/JCO.2007.15.0284
81. Martinet L., Garrido I., Filleron T., Guellec S. L., Bellard E., Fournie J.-J., Rochaix P., Girard J.-P., Human solid tumors contain high endothelial venules: association with T- and B-lymphocyte infiltration and favorable prognosis in breast cancer. Cancer Research 2011 71 17 5678 5687 2-s2.0-80052236068 10.1158/0008-5472.CAN-11-0431
82. Schneider C., Teufel A., Yevsa T., Adaptive immunity suppresses formation and progression of diethylnitrosamine-induced liver cancer. Gut 2012. In press
83. 8+ T-CeII recruitment. Cancer Research 2009 69 7 3077 3085 2-s2.0-66149156276 10.1158/0008-5472.CAN-08-2281
84. Hirano S., Iwashita Y., Sasaki A., Kai S., Ohta M., Kitano S., Increased mRNA expression of chemokines in hepatocellular carcinoma with tumor-infiltrating lymphocytes. Journal of Gastroenterology and Hepatology 2007 22 5 690 696 2-s2.0-34247271266 10.1111/j.1440-1746.2006.04551.x (Pubitemid 46608377)
85. Hong M., Puaux A.-L., Huang C., Loumagne L., Tow C., Mackay C., Kato M., Prévost-Blondel A., Avril M.-F., Nardin A., Abastado J.-P., Chemotherapy induces intratumoral expression of chemokines in cutaneous melanoma, favoring T-cell infiltration and tumor control. Cancer Research 2011 71 22 6997 7009 2-s2.0-81155154274 10.1158/0008-5472.CAN-11-1466
86. Koizumi K., Hojo S., Akashi T., Yasumoto K., Saiki I., Chemokine receptors in cancer metastasis and cancer cell-derived chemokines in host immune response. Cancer Science 2007 98 11 1652 1658 2-s2.0-34748820033 10.1111/j.1349-7006.2007.00606.x (Pubitemid 47487897)
87. Fulton A. M., The chemokine receptors CXCR4 and CXCR3 in cancer. Current Oncology Reports 2009 11 2 125 131 2-s2.0-60349085081 10.1007/s11912-009-0019-1
88. Quezada S. A., Peggs K. S., Simpson T. R., Allison J. P., Shifting the equilibrium in cancer immunoediting: from tumor tolerance to eradication. Immunological Reviews 2011 241 1 104 118 2-s2.0-79954533158 10.1111/j.1600-065X. 2011.01007.x
89. Gajewski T. F., Cancer immunotherapy. Molecular Oncology 2012 6 2 242 250 2-s2.0-84860427686 10.1016/j.molonc.2012.01.002
90. Mantovani A., Romero P., Palucka A. K., Marincola F. M., Tumour immunity: effector response to tumour and role of the microenvironment. The Lancet 2008 371 9614 771 783 2-s2.0-39649098678 10.1016/S0140-6736(08)60241-X
91. Bodey B., Spontaneous regression of neoplasms: new possibilities for immunotherapy. Expert Opinion on Biological Therapy 2002 2 5 459 476 2-s2.0-0035987389 10.1517/14712598.2.5.459 (Pubitemid 34716730)
92. Kalialis L. V., Drzewiecki K. T., Klyver H., Spontaneous regression of metastases from melanoma: review of the literature. Melanoma Research 2009 19 5 275 282 2-s2.0-73349134996 10.1097/CMR.0b013e32832eabd5
93. Saleh F., Renno W., Klepacek I., Ibrahim G., Dashti H., Asfar A., Behbehani A., Al-Sayer H., Dashti A., Kerry C., Direct evidence on the immune-mediated spontaneous regression of human cancer: an incentive for pharmaceutical companies to develop novel anti-cancer vaccine. Current Pharmaceutical Design 2005 11 27 3531 3543 2-s2.0-24944477490 10.2174/138161205774414556 (Pubitemid 41300758)
94. Rosenberg S. A., Dudley M. E., Adoptive cell therapy for the treatment of patients with metastatic melanoma. Current Opinion in Immunology 2009 21 2 233 240 2-s2.0-65249173447 10.1016/j.coi.2009.03.002
95. Gillgrass A., Ashkar A., Stimulating natural killer cells to protect against cancer: recent developments. Expert Review of Clinical Immunology 2011 7 3 367 382 2-s2.0-79957487341 10.1586/eci.10.102
96. Lee S. K., Gasser S., The role of natural killer cells in cancer therapy. Frontiers in Bioscience 2010 2 380 391 2-s2.0-77954483709
97. Alderson K. L., Sondel P. M., Clinical cancer therapy by NK cells via antibody-dependent cell-mediated cytotoxicity. Journal of Biomedicine and Biotechnology 2011 2011 7 379123 2-s2.0-80052658231 10.1155/2011/379123
98. Schreiber T. H., Raez L., Rosenblatt J. D., Podack E. R., Tumor immunogenicity and responsiveness to cancer vaccine therapy: the state of the art. Seminars in Immunology 2010 22 3 105 112 2-s2.0-77953610923 10.1016/j.smim.2010.02.001
99. Slingluff C. L., The present and future of peptide vaccines for cancer: single or multiple, long or short, alone or in combination? Cancer Journal 2011 17 5 343 350 2-s2.0-80053343794 10.1097/PPO.0b013e318233e5b2
100. Kantoff P. W., Higano C. S., Shore N. D., Berger E. R., Small E. J., Penson D. F., Redfern C. H., Ferrari A. C., Dreicer R., Sims R. B., Xu Y., Frohlich M. W., Schellhammer P. F., Sipuleucel-T immunotherapy for castration-resistant prostate cancer. New England Journal of Medicine 2010 363 5 411 422 2-s2.0-77955066199 10.1056/NEJMoa1001294
101. Farrell G., Prevention of hepatocellular carcinoma in the Asia-Pacific region: consensus statements. Journal of Gastroenterology and Hepatology 2010 25 4 657 663 2-s2.0-77950136782 10.1111/j.1440-1746.2009.06167.x
102. Kane M. A., Global implementation of human papillomavirus (HPV) vaccine: lessons from hepatitis B vaccine. Gynecologic Oncology 2010 117 2 S32 S35 2-s2.0-77949488246 10.1016/j.ygyno.2010.01.029
103. Chang M. H., Hepatitis B virus and cancer prevention. Recent Results in Cancer Research 2011 188 75 84 2-s2.0-79551552359 10.1007/978-3-642-10858-76
104. Albers A. E., Siniković B., Banko A. V., Jovanović S., Kaufmann A. M., Developments in therapeutic human papillomavirus vaccination. Acta chirurgica Iugoslavica 2009 56 3 29 37 2-s2.0-77950343308 10.2298/ACI0903029A
105. Roden R., Monie A., Wu T. C., The impact of preventive HPV vaccination. Discovery medicine 2006 6 35 175 181 2-s2.0-33947600814
106. Moschella F., Proietti E., Capone I., Belardelli F., Combination strategies for enhancing the efficacy of immunotherapy in cancer patients. Annals of the New York Academy of Sciences 2010 1194 169 178 2-s2.0-77951847280 10.1111/j.1749-6632.2010.05464.x
107. Antony G. K., Dudek A. Z., Interleukin 2 in cancer therapy. Current Medicinal Chemistry 2010 17 29 3297 3302 2-s2.0-77957936264
108. Grillo-López A. J., White C. A., Dallaire B. K., Varns C. L., Shen C. D., Wei A., Leonard J. E., McClure A., Weaver R., Cairelli S., Rosenberg J., Rituximab: the first monoclonal antibody approved for the treatment of lymphoma. Current Pharmaceutical Biotechnology 2000 1 1 1 9 2-s2.0-17644447104
109. Hortobagyi G. N., Trastuzumab in the treatment of breast cancer. New England Journal of Medicine 2005 353 16 1734 1736 2-s2.0-26844559765 10.1056/NEJMe058196 (Pubitemid 41464714)
110. De Cerio A. L. D., Zabalegui N., Rodríguez-Calvillo M., Inogés S., Bendandi M., Anti-idiotype antibodies in cancer treatment. Oncogene 2007 26 25 3594 3602 2-s2.0-34249733734 10.1038/sj.onc.1210371 (Pubitemid 46842706)
111. Meyer T., Stockfleth E., Clinical investigations of Toll-like receptor agonists. Expert Opinion on Investigational Drugs 2008 17 7 1051 1065 2-s2.0-48249107883 10.1517/13543784.17.7.1051
112. Adams S., Toll-like receptor agonists in cancer therapy. Immunotherapy 2009 1 6 949 964 2-s2.0-77953469710 10.2217/imt.09.70
113. Garland S. M., Imiquimod. Current Opinion in Infectious Diseases 2003 16 2 85 89 2-s2.0-0037398221 (Pubitemid 36521020)
114. Urosevic M., Dummer R., Role of imiquimod in skin cancer treatment. American Journal of Clinical Dermatology 2004 5 6 453 458 2-s2.0-12944304592 10.2165/00128071-200405060-00010 (Pubitemid 40175263)
115. Rubin B., Gairin J. E., Concepts and ways to amplify the antitumor immune response. Current Topics in Microbiology and Immunology 2011 344 97 128 2-s2.0-79959779690 10.1007/82201089
116. Braun S. E., Chen K., Foster R. G., Kim C. H., Hromas R., Kaplan M. H., Broxmeyer H. E., Cornetta K., The CC chemokine CK β -11/MIP-3 β /ELC/exodus 3 mediates tumor rejection of murine breast cancer cells through NK cells. Journal of Immunology 2000 164 8 4025 4031 2-s2.0-0034655163 (Pubitemid 30215056)
117. 8+ T cells in metastases from melanoma patients. Journal of Clinical Investigation 2011 121 6 2350 2360 2-s2.0-79957925314 10.1172/JCI46102
118. Klebanoff C. A., Acquavella N., Yu Z., Restifo N. P., Therapeutic cancer vaccines: are we there yet? Immunological Reviews 2011 239 1 27 44 2-s2.0-78650574270 10.1111/j.1600-065X.2010.00979.x
119. Hirano F., Kaneko K., Tamura H., Dong H., Wang S., Ichikawa M., Rietz C., Flies D. B., Lau J. S., Zhu G., Tamada K., Chen L., Blockade of B7-H1 and PD-1 by monoclonal antibodies potentiates cancer therapeutic immunity. Cancer Research 2005 65 3 1089 1096 2-s2.0-13444270323 (Pubitemid 40216472)
120. Dotti G., Blocking PD-1 in cancer immunotherapy. Blood 2009 114 8 1457 1458 2-s2.0-70449475132 10.1182/blood-2009-05-223412
121. Lipson E. J., Drake C. G., Ipilimumab: an anti-CTLA-4 antibody for metastatic melanoma. Clinical Cancer Research 2011 17 22 6958 6962 2-s2.0-81255138488 10.1158/1078-0432.CCR-11-1595
122. Prieto P. A., Yang J. C., Sherry R. M., Hughes M. S., Kammula U. S., White D. E., Levy C. L., Rosenberg S. A., Phan G. Q., CTLA-4 blockade with ipilimumab: long-term follow-up of 177 patients with metastatic melanoma. Clinical Cancer Research 2012 18 7 2039 2047 2-s2.0-84859393995 10.1158/1078-0432.CCR-11-1823
123. DeLong P., Tanaka T., Kruklitis R., Henry A. C., Kapoor V., Kaiser L. R., Sterman D. H., Albelda S. M., Use of cyclooxygenase-2 inhibition to enhance the efficacy of immunotherapy. Cancer Research 2003 63 22 7845 7852 2-s2.0-0345275867 (Pubitemid 37466718)
124. Dempke W., Rie C., Grothey A., Schmoll H. J., Cyclooxygenase-2: a novel target for cancer chemotherapy? Journal of Cancer Research and Clinical Oncology 2001 127 7 411 417 2-s2.0-0034994651 10.1007/s004320000225 (Pubitemid 32524357)
125. Dannull J., Su Z., Rizzieri D., Yang B. K., Coleman D., Yancey D., Zhang A., Dahm P., Chao N., Gilboa E., Vieweg J., Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells. Journal of Clinical Investigation 2005 115 12 3623 3633 2-s2.0-30144444279 10.1172/JCI25947 (Pubitemid 43121851)
126. Morse M. A., Hobeika A. C., Osada T., Serra D., Niedzwiecki D., Kim Lyerly H., Clay T. M., Depletion of human regulatory T cells specifically enhances antigen-specific immune responses to cancer vaccines. Blood 2008 112 3 610 618 2-s2.0-50949115267 10.1182/blood-2008-01-135319
127. Woller N., Knocke S., Mundt B., Gürlevik E., Strüver N., Kloos A., Boozari B., Schache P., Manns M. P., Malek N. P., Sparwasser T., Zender L., Wirth T. C., Kubicka S., Kühnel F., Virus-induced tumor inflammation facilitates effective DC cancer immunotherapy in a Treg-dependent manner in mice. Journal of Clinical Investigation 2011 121 7 2570 2582 2-s2.0-79959956606 10.1172/JCI45585
128. Zitvogel L., Apetoh L., Ghiringhelli F., André F., Tesniere A., Kroemer G., The anticancer immune response: indispensable for therapeutic success? Journal of Clinical Investigation 2008 118 6 1991 2001 2-s2.0-45749134564 10.1172/JCI35180 (Pubitemid 351872317)
129. Balachandran V. P., Cavnar M. J., Zeng S., Bamboat Z. M., Ocuin L. M., Obaid H., Sorenson E. C., Popow R., Ariyan C., Rossi F., Besmer P., Guo T., Antonescu C. R., Taguchi T., Yuan J., Wolchok J. D., Allison J. P., Dematteo R. P., Imatinib potentiates antitumor T cell responses in gastrointestinal stromal tumor through the inhibition of Ido. Nature Medicine 2011 17 9 1094 1100 2-s2.0-80052493233 10.1038/nm.2438
130. 8+ T cell memory and tumor immunity. Immunity 2011 34 4 541 553 2-s2.0-79954623272 10.1016/j.immuni.2011.04.006
131. Gasser S., Raulet D., The DNA damage response, immunity and cancer. Seminars in Cancer Biology 2006 16 5 344 347 2-s2.0-33748207131 10.1016/j.semcancer.2006.07.004 (Pubitemid 44311502)
132. Zitvogel L., Kepp O., Kroemer G., Immune parameters affecting the efficacy of chemotherapeutic regimens. Nature Reviews Clinical Oncology 2011 8 3 151 160 2-s2.0-79952390627 10.1038/nrclinonc.2010.223
133. Bocci G., Nicolaou K. C., Kerbel R. S., Protracted low-dose effects on human endothelial cell proliferation and survival in vitro reveal a selective antiangiogenic window for various chemotherapeutic drugs. Cancer Research 2002 62 23 6938 6943 2-s2.0-0036897097 (Pubitemid 35424084)
134. Lake R. A., Robinson B. W. S., Immunotherapy and chemotherapya practical partnership. Nature Reviews Cancer 2005 5 5 397 405 2-s2.0-18344375283 10.1038/nrc1613 (Pubitemid 40637831)